MedTrace Logo

CJD (Creutzfeldt-Jakob Disease) Quinacrine Study

NCT00183092 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 69

Last updated 2014-06-09

Study results available
· View outcomes & findings →

Summary

The purpose of this clinical trial is to determine the effectiveness of the medication quinacrine on survival in sporadic Creutzfeldt-Jakob disease (sCJD).

Conditions

  • Creutzfeldt-Jakob Disease

Interventions

DRUG

Quinacrine

100mg by mouth three times a day

DRUG

Placebo

100mg by mouth three times a day

Sponsors & Collaborators

Principal Investigators

  • Michael Geschwind, MD, PhD · UCSF Memory & Aging Center, University of California, San Francisco

  • Bruce L. Miller, MD · UCSF Memory & Aging Center, University of California, San Francisco

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2005-04-30
Primary Completion
2012-06-30
Completion
2012-06-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00183092 on ClinicalTrials.gov